Bedrijfsoverzicht
ADMA Biologics, Inc. is a biopharmaceutical entity dedicated to the development, manufacturing, and marketing of specialty plasma-derived biologics designed for the treatment of immune deficiencies and infectious diseases, with operations extending across the United States and international markets. The company functions within the Healthcare sector and specifically operates in the Biotechnology industry, positioning itself to capitalize on the specialized demand for rare plasma products that standard pharmaceutical manufacturing cannot easily replicate. As of the latest data, the organization employs 640 individuals and holds a market capitalization of $2.31 billion, while generating annual revenue of $510.17 million. These valuation and revenue figures indicate that ADMA Biologics occupies a significant niche within the biotechnology landscape, supported by a substantial operational footprint that facilitates complex manufacturing processes for high-value biologics. The combination of a $2.31 billion market cap and half-a-billion-dollar revenue stream suggests a company with established commercial traction and the financial scale necessary to sustain R&D and manufacturing investments in a capital-intensive industry.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $510.17 million and a net income of $146.93 million, supported by an EBITDA of $199.54 million. The substantial gap between the reported net income and EBITDA, alongside a reported free cash flow of $-18,154,876, reveals a cost structure where significant capital expenditures are required to maintain manufacturing capabilities, resulting in cash burn despite profitable accounting earnings. Three distinct margin metrics provide insight into operational efficiency: the gross margin stands at 57.4%, indicating high value retention after the cost of goods sold; however, the operating margin is listed at -123.4%, which reflects heavy investment in operating expenses that have not yet been fully offset by current operational scaling; conversely, the profit margin is stated at 28.8%, suggesting that non-operating income or specific accounting treatments contribute significantly to the bottom line. The balance sheet presents a unique liquidity profile with reported cash reserves of $55.92 billion against total debt of $97.67 billion, creating a scenario where the company holds substantially more cash on hand than its debt obligations. This disparity is further highlighted by a debt-to-equity ratio of 110.67, which mathematically implies a leveraged structure, yet the massive cash reserve of $55.92 billion suggests the company is not facing a standard solvency crisis but rather manages debt in a context of extreme liquidity. Short-term liquidity is robust, evidenced by a current ratio of 6.71, which indicates the company possesses more than six dollars in current assets for every dollar of current liabilities, providing ample buffer for immediate obligations. Finally, return metrics demonstrate management effectiveness with a return on equity of 35.6% and a return on assets of 21.5%, revealing that the company generates significant returns relative to the capital shareholders and creditors have invested, despite the complexities presented by the operating margin figures.
Waarderingsbeoordeling
Valuation multiples for ADMA Biologics show a trailing P/E ratio of 16.17 compared to a forward P/E of 7.03, implying that the market expects earnings growth that would allow the forward multiple to converge with or exceed the trailing figure over time. The price-to-book ratio is recorded at 4.83, which indicates that the market values the company at nearly five times its net asset book value, reflecting a premium assigned to its intangible assets and future growth potential rather than just tangible balance sheet items. Alternative valuation metrics such as a price-to-sales ratio of 4.53 and an EV/EBITDA of 220.80 suggest that the company is valued primarily on its revenue generation and earnings power rather than traditional asset backing, a common characteristic in the biotechnology sector where future cash flows are projected to be substantial. Price action over the last year has been volatile, with a 52-week high of $25.67 and a 52-week low of $7.21, placing the current trading price in a range that fluctuates significantly from these historical extremes. The beta value of 0.82 indicates that the stock's price volatility is lower than the broader market average, suggesting that ADMA Biologics tends to move with less intensity than the overall market index during periods of economic fluctuation.
Growth & Income
Revenue growth for the company is reported at 15.9% year-over-year, while earnings growth is listed as N/A, indicating that while top-line expansion is occurring, the specific rate of earnings acceleration is not currently quantified in the available data. Because earnings growth data is unavailable, a direct comparison between earnings and revenue growth rates cannot be made, preventing a definitive statement on whether profitability is scaling faster than sales volume. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all of its earnings to fund research and development, manufacturing expansion, and other strategic initiatives rather than distributing cash to shareholders. This reinvestment strategy is typical for biotechnology companies in the growth phase, prioritizing capital allocation toward sustaining the pipeline of plasma-derived biologics over providing current income to investors. The overall growth and income profile is characterized by strong revenue expansion and a total absence of dividend distribution, aligning the company's trajectory with long-term value creation through product innovation rather than current yield.